Cervical Cancer and Human Papillomavirus (HPV)
The human papillomavirus (HPV) is the main cause of cervical cancer. HPV, which also causes genital warts, is spread primarily through sexual contact. About half of all sexually active young women become infected with the virus, but only 10% remain infected for more than 5 years.
The risk for cervical cancer is highest for women who have persistent long-term infection with one of the two high-risk strains of HPV. Half of all cervical cancer diagnoses occur in women ages 35 - 55.
Two vaccines, Gardasil and Cervarix, are available to prevent (not treat) cervical cancer in girls and young women. Gardasil is also approved for boys. Both vaccines protect against HPV-16 and HPV-18, the two HPV strains that cause most cases of cervical cancer. Gardasil, but not Cervarix, also protects against HPV-6 and HPV-11, the two viruses that cause most cases of genital warts.
Current immunization guidelines recommend the HPV vaccine for all girls ages 11 - 12. In 2011, the advisory committee for the U.S. Centers for Disease Control (CDC) recommended that the vaccine should also be given to boys ages 11 - 12.
Cervical Cancer Screening
In 2011, the United States Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS) each revised their respective guidelines for cervical cancer screening. The proposed guidelines recommend:
- Women ages 21 - 65. Cervical cancer screening should begin at age 21 and be repeated once every 3 years until the age of 65.
- Women ages 65 and older. Women age 65 and older, as well as those who have had a hysterectomy that includes removal of the cervix, no longer need Pap tests
Most organizations agree that screening for HPV should not be performed in women under age 30, but they differ in their recommendations for older women.
The ACS recommends that women over age 30 receive the HPV test in combination with the Pap test every 3 - 5 years. The American College of Obstetricians and Gynecologists (ACOG) advises that the HPV test can be used along with the Pap test in women ages 30 and older. The USPSTF states that there is not yet enough evidence to recommend for or against HPV screening.
One concern is that HPV is very common and most infections clear up on their own. A positive HPV test may result in unnecessary overtreatment.
The cervix is the lower third portion of the uterus (womb). It serves as a neck to connect the uterus to the vagina. The opening of the cervix, called the os, remains small and narrow, except during childbirth when it widens to allow a baby to pass from the uterus into the vagina.
The uterus is a hollow muscular organ located in the female pelvis between the bladder and rectum. The ovaries produce the eggs that travel through the fallopian tubes. Once the egg has left the ovary it can be fertilized and implant itself in the lining of the uterus. The main function of the uterus is to nourish the developing fetus prior to birth.
Cervical cancer develops in the thin layer of cells called the epithelium, which cover the cervix. Cells found in this tissue have different shapes:
- Squamous cells (flat and scaly). Most cervical cancer arises from changes in the squamous cells of the epithelium (squamous cell carcinoma).
- Columnar cells (column-like). These cells line the cervical glands. Cancers found here are known as adenocarcinomas.
- Mixed carcinomas are cells that combine features of squamous cells and adenocarcinomas.
Cervical cancer usually begins slowly with precancerous abnormalities, and even if cancer develops, it generally progresses very gradually. Cervical cancer is the most preventable type of cancer and is very treatable in its early stages. Regular Pap tests and human papillomavirus (HPV) screening can help detect this disease early.
Precancerous Changes in the Cervix
Dysplasia is a term that refers to a precancerous condition. It may become cancerous, but not always. In the case of cervical cancer, dysplasia indicates that some cells on the outside of the cervix (squamous epithelial cells) are abnormal in size and shape and are beginning to grow. However, the abnormal cells are still confined to the surface (epithelial layer)
These types of changes are generally first noted in the results of a Pap smear. They will be reported as one of the following:
- Atypical squamous cells (ASC)
- Low-grade squamous intraepithelial lesion (LGSIL)
- High-grade squamous intraepithelial lesion (HGSIL)
(See Pap smear section in Diagnosis for more detail about these terms.)
If further testing is needed, a colposcopy is usually performed. Results for colposcopy are reported as cervical intraepithelial neoplasia (CIN).These precancerous changes are categorized according to severity: CIN I, CIN II, and CIN III. (See Colposcopy section in Diagnosis for more detail about these terms.)
CIN III is considered the same as carcinoma in situ (CIS) or Stage 0 cervical cancer. The cancer has not yet invaded deeper tissues. However, if not surgically removed, there is a high chance it can progress to invasive cancer.
Click the icon to see an image of cervical dysplasia.
Invasive Cervical Cancer
The cells of the epithelium rest on a very thin layer called the basement membrane. Invasive cervical cancer occurs when cancer cells in the epithelium cross this membrane and invade the stroma, the underlying supportive tissue of the cervix.
In later stages, the original cancer may spread to areas surrounding the uterus and cervix or near organs such as the bladder or rectum. It may also spread to distant sites in the body through the bloodstream or the lymph nodes.
The human papillomavirus (HPV) is the main cause and risk factor of cervical cancer. HPV has been detected in virtually all invasive cervical cancers. About 1 in 4 U.S. females ages 14 - 59 are infected with HPV. The prevalence of HPV is highest (45%) in women ages 20 - 24.
How HPV Is Transmitted. HPV is spread primarily by having sex with a partner infected with HPV. HPV infection around the genitals is common, although most people have no symptoms. Some people with HPV infection will have visible genital warts. They are raised, flesh-colored soft growths that may occur singly or in clusters.
The HPV virus can cause warts on the penis, vulva, urethra, or around the anus. In women, HPV can invade the vagina and cervix. Vaginal and cervical warts are flat and not easily visible without special procedures. However, both men and women can be infected with the HPV virus and not have any visible warts on the genitalia. This is because this virus lives in the cells.
Most sexually active young women become infected with this virus, but only 10% remain infected for more than 5 years. In most cases, HPV goes away on its own. The risk for cervical cancer in infected women appears to be highest in those with persistent long-term infection with high-risk HPV strains. Generally, those infected for longer than 5 years have a higher risk (about 50% above normal).
How HPV Contributes to Cervical Cancer. Research suggests that most cervical cancers develop when certain genetic HPV strains activate certain oncogenes (cancer-causing genes). These oncogenes interfere with certain protective proteins, which normally limit cell growth. Once they are blocked, cell growth can accelerate, leading to tumor development and cancer.
HPV Genetic Types. There are more than 100 types of HPV. More than 30 genetic variants of human papillomaviruses can be passed through sexual contact from one person to another. People initially infected by one type of HPV are still at risk for infection from other types.
Low-risk HPV types, such as HPV 6 and 11, cause genital warts and cervical intraepithelial neoplasia I (CIN I). High-risk HPV types can cause cervical cancer. Less commonly, high-risk HPV types can cause as well as cancers of the vagina, vulva, anus, penis, oropharyngeal (throat, tongue, soft palate) and possibly lung cancers.
Of the high-risk types, HPV types 16 and 18 are known to be particularly dangerous. These two genetic types and six others (31, 33, 35, 45, 52, and 58) account for 95% of HPV-related cervical cancers. Other high-risk types are 39, 51, 56, 59, 68, 73, and 82. All are associated with cervical intraepithelial neoplasia II (CIN II) and cervical intraepithelial neoplasia III (CIN III). Types 26, 53, and 66 are also considered high risk.
The high-risk viruses generally produce flat and nearly invisible growths, compared to the usually harmless warts caused by low-risk HPV viruses.
About 13,000 new cases of invasive cervical cancer are diagnosed each year in the U.S. However, the number of new cervical cancer cases has been declining steadily over the past decades.
Although it is the most preventable type of cancer, each year cervical cancer kills about 4,000 women in the U.S. and about 300,000 women worldwide. In the United States, cervical cancer mortality rates plunged by 74% from 1955 - 1992 thanks to increased screening and early detection with the Pap test.
Fifty percent of cervical cancer diagnoses occur in women ages 35 - 54, and about 20% occur in women over 65 years of age. The median age of diagnosis is 48 years. About 15% of women develop cervical cancer between the ages of 20 - 30.
Cervical cancer is extremely rare in women younger than age 20. However, many young women become infected with multiple types of human papillomavirus, which then can increase their risk of getting cervical cancer in the future. Young women with early abnormal changes who do not have regular examinations are at high risk for localized cancer by the time they are age 40, and for invasive cancer by age 50.
Socioeconomic and Ethnic Factors
Although the rate of cervical cancer has declined among both Caucasian and African-American women over the past decades, it remains much more prevalent in African-Americans -- whose death rates are twice as high as Caucasian women. Hispanic American women have more than twice the risk of invasive cervical cancer as Caucasian women, also due to a lower rate of screening.
These differences, however, are almost certainly due to social and economic differences. Numerous studies report that high poverty levels are linked with low screening rates. In addition, lack of health insurance, limited transportation, and language difficulties hinder a poor woman’s access to screening services.
High Sexual Activity
Human papillomavirus (HPV) is the main risk factor for cervical cancer. In adults, the most important risk factor for HPV is sexual activity with an infected person. Women most at risk for cervical cancer are those with a history of multiple sexual partners, sexual intercourse at age 17 years or younger, or both. A woman who has never been sexually active has a very low risk for developing cervical cancer.
Sexual activity with multiple partners increases the likelihood of many other sexually transmitted infections (chlamydia, gonorrhea, syphilis). Studies have found an association between chlamydia and cervical cancer risk, including the possibility that chlamydia may prolong HPV infection.
Women have a higher risk of cervical cancer if they have a first-degree relative (mother, sister) who has had cervical cancer.
Use of Oral Contraceptives
Studies have reported a strong association between cervical cancer and long-term use of oral contraception (OC). Women who take birth control pills for more than 5 - 10 years appear to have a much higher risk HPV infection (up to four times higher) than those who do not use OCs. (Women taking OCs for fewer than 5 years do not have a significantly higher risk.)
The reasons for this risk from OC use are not entirely clear. Women who use OCs may be less likely to use a diaphragm, condoms, or other methods that offer some protection against sexual transmitted diseases, including HPV. Some research also suggests that the hormones in OCs might help the virus enter the genetic material of cervical cells.
Having Many Children
Studies indicate that having many children increases the risk for developing cervical cancer, particularly in women infected with HPV.
Smoking is associated with a higher risk for precancerous changes (dysplasia) in the cervix and for progression to invasive cervical cancer, especially for women infected with HPV.
Women with weak immune systems, such as those with HIV/AIDS, are more susceptible to acquiring HPV. Immunocompromised patients are also at higher risk for having cervical precancer develop rapidly into invasive cancer.
From 1938 - 1971, diethylstilbestrol (DES), an estrogen-related drug, was widely prescribed to pregnant women to help prevent miscarriages. The daughters of these women face a higher risk for cervical cancer. DES is no longer prescribed.
The best way to prevent cervical cancer is to avoid getting infected with human papillomavirus (HPV). Because HPV is sexually transmitted, practicing safe sex and limiting the number of sexual partners can help reduce risk. A vaccine can protect against the major cancer-causing HPV strains in girls and young women who have not yet been exposed to the virus. Regular Pap tests remain the most effective way of catching cervical cancer while it is in its earliest precancerous stages and preventing the development of invasive cervical cancer.
Two vaccines are approved by the FDA to prevent either human papillomavirus (HPV) or cervical cancer: Gardasil and Cervarix.
Gardasil is approved for:
- Girls and women ages 9 - 26, for protection against HPV-16 and HPV-19, the HPV strains that cause most cases of cervical cancer. It also protects against HPV-6 and HPV-11, which cause 90% of cases of genital warts.
- Boys and young men ages 9 - 26 years to prevent genital warts.
- Gardasil is also approved to prevent anal cancer in people ages 9 - 26 years.
- Because it protects against four strains of HPV, Gardasil is called a quadrivalent or HPV4 vaccine.
Cervarix is approved for:
- Girls and women ages 10 - 26 for protection against HPV-16 and HPV-19, the HPV strains that cause most cases of cervical cancer.
- Cervarix does not protect against genital warts.
- Cervarix has not been approved for use in boys or men.
- Because it protects against two strains of HPV, Cervarix is called a bivalent or HPV2 vaccine.
Three steps generally take place before any vaccine is widely used. First the FDA approves the vaccine. Next, organizations such as U.S. Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Cancer Society (ACS) make recommendations about who should routinely receive the vaccine. Finally, organizations such as the Centers for Disease Control (CDC) write guidelines based on these recommendations.
Current immunization guidelines recommend:
- Routine vaccination for girls ages 11 - 12 years. The vaccine should be administered in 3 doses, with the second and third doses administered 2 and 6 months after the first dose. The HPV vaccine can be given at the same time as other vaccines. Either Gardasil or Cervarix may be used, and one vaccine can be substituted for another in the 3-dose series.
- Girls as young as age 9 can receive the vaccine at their doctors’ discretion.
- Girls and women ages 13 - 26 who have not been previously immunized or who have not completed the full vaccine series should get vaccinated to catch up on missed doses. [The U.S. Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) recommend catch-up doses for ages 13 - 26. The American Cancer Society (ACS) recommends catch-up for ages 13 - 18. The ACS suggests that women ages 19 - 26 discuss with their doctors the relative risks and benefits of vaccination.]
- Women should not get the vaccine during pregnancy.
- In 2011, the ACIP recommended routine 3-dose vaccination with Gardasil for all 11 - 12 year-old boys. The ACP also recommended vaccination for all boys ages 13 - 21 years who have not yet received the HPV4 vaccine.
The HPV vaccine can only prevent -- not treat -- HPV infection, genital warts, and cervical cancer. Because the vaccine cannot protect females who are already infected with HPV, doctors recommend that girls and boys get vaccinated before they become sexually active. Studies indicate that the vaccine is nearly 100% effective in preventing cervical cancer and genital warts (caused by the HPV types covered in the vaccine) when given prior to HPV exposure. However, young women who are sexually active may still derive some benefit from the vaccine, at least for protection against any of the four HPV strains that they have not yet acquired.
The most common side effects of the vaccine include discomfort or pain at the injection site, headache, and mild fever.
These vaccines do not protect against all types of cancer-causing HPV. Women should receive regular screening to detect any early signs of cervical cancer. For girls and women who have been sexually active before they receive the vaccine, screening still provides the best protection against cervical cancer.
Condoms provide some protection against HPV as well as other sexually transmitted diseases.
Male circumcision may possibly reduce the risk of HPV, but it does not completely prevent it. Men who are circumcised should still use condoms.
Intrauterine Devices (IUDs)
Some evidence suggests that the intrauterine device (IUD) may help protect against cervical cancer. The IUD is a type of birth control that is inserted into the uterus by a health professional. It is a small plastic T-shaped device that contains either the hormone progesterone or copper.
In a large study, women who used an IUD for birth control had half the risk of developing cervical cancer as those who did not use an IUD. The IUD did not decrease HPV infection, but did seem to affect the likelihood that HPV would progress into cervical cancer. Researchers are not certain exactly how the IUD reduces cervical cancer risk, but think that the process of inserting or removing the device may destroy precancerous lesions.
Regular Pap tests are the most effective way to diagnose cervical cancer when it is still in its earliest, most curable stages. [For more information, see Diagnosis and Screening section of this report.]
A patient’s prognosis for cervical cancer depends on the stage of the cancer, the type of cervical cancer, and the size of the tumor.
General Survival Rates in Women with Cervical Cancer
Over the past 30 years, the death rate from cervical cancer has declined significantly. In general, 71% of women with invasive cervical cancer survive for 5 years or more. African-American women tend to have poorer 5-year survival rates than Caucasian women, although survival rates have significantly increased in African-American women in recent years.
Survival Rates and Cervical Cancer Stage
About half of cervical cancer cases are diagnosed when the cancer is confined to the cervix (localized; Stage I). About 35% of cases are diagnosed after the cancer has spread to adjacent areas or lymph nodes (regional; Stage II/III), and about 10% of cases are diagnosed when the cancer has already spread to distant regions (metastasized; Stage IV).
Depending on the stage and spread of cancer, 5-year survival rates are:
- 92% for localized cervical cancer
- 58% for regional cancer
- 17% for metastasized cancer
Most women with dysplasia or pre-invasive cancer have no symptoms. Screening tests, therefore, are very important.
When the cancer becomes invasive, unusual bleeding can occur. Bleeding may stop and start again between regular periods, or there may be bleeding after menopause. Unexpected bleeding can also occur after intercourse or a pelvic exam. Periods sometimes last longer or are heavier than usual. Increased vaginal discharge may be noticeable as well. Pelvic pain or pain during sexual intercourse can occur.
These symptoms are not exclusive to cervical cancer. Sexually transmitted diseases, for instance, can cause similar symptoms.
Diagnosis and Screening
The changes that lead to cervical cancer develop slowly. Screening tests performed during regular gynecologic examinations can detect early changes.
Every year in the U.S. about 50 million women have a Papanicolaou test, better known as the Pap test or Pap smear). Use of the Pap test has significantly reduced the death rate from cervical cancer.
Many women who have a Pap test fail to follow-up for retesting and treatment. Most cases of cervical cancer occur in women who have not had regular Pap tests.
The Procedure. The most accurate test results are obtained 12 - 14 days after menstruation begins. Women should not douche or have intercourse within 48 hours of the test. Douches and spermicidal creams may clean out abnormal cells and interfere with the results of a Pap test. (In general, douching is not recommended at all.) A Pap test is usually painless, although some women may have some discomfort.
A Pap test is a simple, relatively inexpensive procedure that can easily detect cancerous or precancerous conditions.
- The test is done in a doctor's office. The woman removes her clothes from the waist down and puts on a medical gown. She lies on her back on the examination table, bends her knees, and puts her feet in supports (called stirrups) at the end of the table.
- The doctor inserts a plastic or metal device (called a speculum) into her vagina to widen it.
- Using a spatula, brush, or both, the doctor gently scrapes the surface of the cervix, and sometimes the upper vagina, to gather living cells. The doctor will also obtain cells from inside the cervical canal. The scraping is completely painless.
- The cells are preserved, stained for microscopic viewing, and then analyzed under a microscope by a specialist known as a cytopathologist.
Reliability and Accuracy. The Pap test is not a perfectly reliable measure of a woman's risk for cervical cancer. In general, about 10% of Pap tests have abnormal results, but only about 0.1% of the women who have these results actually have cancer. In most cases, abnormal cells are low grade and not likely to progress to cancer or are due to benign conditions, including natural cell changes after menopause.
No test is 100% accurate, and it is possible for the Pap test to miss the presence of cancer. However, if abnormal cells are missed on one test, they are likely to be spotted during the next one without a significant danger.
New tests and methods have been developed to improve the accuracy of the Pap test in detecting cancer cells. For example, there are several computerized Pap test systems that are used to rescreen the original smear. These systems are either used to detect abnormal samples that may have been missed by manual review methods or are used in place of a human cytotechnologist. There is not yet enough evidence to know whether or not computerized methods are superior to conventional Pap testing.
Newer, thin-layer liquid based tests (ThinPrep, SurePath) use the original cervical sample, which is rinsed in a special solution to thin the mucus (rather than dried). The fluid is examined for evidence of abnormal cells as well as HPV and other early abnormalities. Some studies have found liquid-based Pap tests to be more accurate than the standard Pap test.
Current Cervical Cancer Screening Recommendations
General guidelines for cervical cancer screening recommend:
Initial Screening. Women should begin to undergo Pap tests at age 21 regardless of whether or not they have been sexually active.
Women Ages 21 - 65. Women ages 21 - 65 who are at average risk for cervical cancer should be screened once every 3 years with either a conventional or liquid-based Pap test.
Women Ages 65 and Older. Women age 65 and older no longer need Pap tests as long as they have had three negative (normal) Pap tests within the last 10 years.
After a Hysterectomy. Women who have had a total hysterectomy (removal of uterus and cervix) for non-cancer reasons can discontinue Pap testing. Women who have had a hysterectomy that preserves the cervix (called a supracervical hysterectomy) should continue with Pap screening.
Tests for Human Papillomavirus
A human papillomavirus (HPV) DNA test can identify the high-risk types of HPV that are known to cause cervical cancer. The test may be used when a Pap test comes back with borderline abnormal or inconclusive results to help provide more information.
There is debate among doctors whether the HPV test should be used as a screening tool. Doctors agree that the test is not recommended for women under age 30. For women over age 30, the American Cancer Society recommends HPV testing in combination with the Pap test every 3 - 5 years. The American College of Obstetricians and Gynecologists advises that the HPV test can be used along with the Pap test for women ages 30 and older. The United States Preventive Services Task Force states there is not yet enough evidence to recommend for or against the HPV test in women over age 30.
One concern about the HPV test is that HPV infections are very common and many of them clear up on their own. Positive test results could result in overtreatment for women who were not likely to develop cervical cancer.
Classifying Cervical Cells and Determining Further Testing
The cells viewed in a cervical smear sample are classified on a scale representing the spectrum of cell changes from normal to cancerous. The Pap test is first characterized as either normal or abnormal.
Once abnormal epithelial cells are identified, the doctor must decide whether the patient needs only repeat Pap tests, a test for the human papillomavirus (HPV) virus, or colposcopy (a procedure used to magnify the cervix and permit detection of lesions for biopsy). To help the doctor make the decision, the abnormal cells are divided into categories, depending on the degree of abnormality, and whether they are squamous or glandular (adenocarcinoma).
The two main types of cervical cell cancer are squamous cell and adenocarcinoma. Squamous cell carcinoma represents the large majority of all cervical cancers. The remaining cases are either a combination of squamous and glandular, or rarer types.
These classifications are based on the 2001 Bethesda System (TBS), which is formulated to standardize the reporting of Pap test results:
Atypical Squamous Cells. Atypical squamous cells (ASC) are mildly abnormal cells on the surface of the cervix. They may simply represent inflammation. Over 80% of these cells become normal, but unfortunately, 5 - 17% of these women have a chance for having cervical intraepithelial neoplasia (CIN) II and III dysplasia, which indicates potentially invasive cells. Atypical squamous cells are further categorized as:
- ASC-US. These atypical squamous cells of undetermined significance (ASC-US) are the lowest risk abnormal cells. Women with these cells should be tested for HPV. If results indicate they are infected with HPV, they should have a colposcopy to determine if the condition is actually at a more aggressive stage. If they do not have HPV they are simply monitored with repeat Pap tests.
- ASC-H. This category refers to the presence of atypical squamous cells, but a doctor cannot exclude possible high-grade squamous intraepithelial lesions. Such women have a higher risk of having CIN II and III. All are referred for colposcopy.
Among those with atypical squamous cells, immunosuppressed women and those with high-risk human papillomavirus infections are at higher risk for cervical intraepithelial neoplasia II and III and should always be given colposcopy. Postmenopausal women with normal immune systems have a lower risk than younger women. In general, the actual risk for cervical cancer in women with atypical squamous cells is only 0.1 - 0.2%.
Squamous Intraepithelial Lesions (SILs). Squamous intraepithelial lesions (SILs) are classified as either low-grade (LGSIL) or high-grade (HGSIL). High-grade SILs are more serious than low-grade SILs, and need to be treated because they can develop into invasive cancer. Pap tests can identify the presence of SILs but not their grade. All patients with SILs should undergo colposcopy. A colposcopy can determine whether SILs are high-grade or low-grade and whether treatment is required.
Atypical Glandular Cells and Adenocarcinoma. Atypical glandular cells pose a higher risk for cancerous changes than atypical squamous cells or low-grade squamous intraepithelial lesions. Patients with atypical glandular cells need colposcopy and endocervical testing. Adenocarcinoma refers to glandular cells that are cancerous.
Colposcopy and Biopsy
The Pap test shows only the presence of abnormal cells. It is useful simply as a screening test that identifies women who may have preinvasive or early cancerous changes. For a definitive diagnosis, the next step is usually colposcopy, during which the cervix is visualized under low power magnification. The surgeon takes samples of suspicious cells for biopsies. A biopsy will determine the stage of the precancerous growth or whether invasive cancer is present.
The Procedure. Colposcopy can be performed in a doctor's office without anesthesia in 10 - 15 minutes. It causes about as much discomfort as mild menstrual cramps:
- First, using a speculum to keep the vagina open, the doctor aims a light at the cervix.
- The doctor then looks through the eyepiece of a special microscope, known as a colposcope, to view the cervix.
- A biopsy (a sampling of the tissue) is taken of suspicious areas, of the endocervical canal (the inner part of the cervix and uterus), and any abnormal-looking areas. This may cause cramping or pinching.
After the colposcopy, the woman may have a brownish discharge from an iron solution called Monsel's solution, which the doctor applies to prevent bleeding. Doctors usually advise sexual abstinence for 1 - 2 weeks.
The precancerous changes from biopsy results of colposcopy are called cervical intraepithelial neoplasia. They are categorized according to severity: CIN I, CIN II, and CIN III.
- CIN I is classified as mild dysplasia. It is equivalent to a low-grade squamous intraepithelia lesion (LGSIL) identified by a Pap test. CIN I may progress if untreated but often goes away without treatment.
- CIN II is classified as moderate dysplasia. It is equivalent to a high-grade squamous intraepithelial lesion (HGSIL) found in a Pap test.
- CIN III is classified as severe dysplasia. It is the most aggressive form of dysplasia. It is also equivalent to a high-grade squamous intraepithelial lesion.
CIN III is considered the same as carcinoma in situ (CIS) or Stage 0 cervical cancer. In both CIN III and CIS the precancerous cells still rest on the surface of the cervix and have not yet invaded deeper tissues. However, if not surgically removed, there is a high chance that CIN III or CIS can progress to invasive cancer.
Follow-Up Procedures. Women with evidence of cervical intraepithelial neoplasia (CIN) or cervical cancer need treatment. Women with biopsies that show low-grade abnormal cells, but whose cervix is otherwise normal, are generally given follow-up colposcopies.
If a biopsy detects invasive cancer, the patient will need additional tests to find out how far the cancer has spread. Tests to stage cancer may include a computed tomography (CT) scan (to check for the spread of the disease to lymph nodes and areas around the pelvic region), chest x-ray, ultrasound, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, and other imaging tests.
Treatment of Pre-Invasive Cancer
Treatment of cervical intraepithelial neoplasia (CIN), including pre-invasive cancer, depends on the type and extent of abnormal changes. Some of the treatments for CIN are also used for early-stage cancer.
- CIN I often goes away on its own. Careful follow up is required to make certain that the Pap smear and colposcopic exam return to normal.
- CIN II or CIN III may turn into invasive cancer if the suspicious area is not removed. This is often done using an outpatient technique called loop electrosurgical excision procedure (LEEP). [See Surgery section.]
- If doctors cannot see extensive areas of CIN II or III with colposcopy or if these areas have spread into the mucous membrane in the cervical canal, a more aggressive procedure called conization (cone biopsy) may be required. [See Surgery section.] Since CIN III is considered equivalent to Stage 0 cervical cancer, other procedures may be used if LEEP or conization are inadequate.
Treatment of Invasive Cervical Cancer
In contrast to cervical intraepithelial neoplasia, cervical cancer represents true invasion of cells beyond the epithelium into surrounding tissue. Cervical cancer may be detected in a biopsy performed during colposcopy for an abnormal Pap smear, or it may be visible to the naked eye when the doctor performs a speculum exam.
After making a diagnosis, the doctor will classify the stage of the cancer according to how far the disease has spread into the lining of the cervix, throughout the cervix, or beyond. Doctors use these classifications to determine treatment and prognosis.
Stages of Cervical Cancer
Stage 0. Stage 0 cancer is also called carcinoma in situ. It is equivalent to CIN III pre-invasive cancer. In stage 0, the cancer cells are confined to the first layer of cervical tissue (the epithelium) lining the cervix and have not yet spread further in the cervix.
Stage I. Stage I is invasive cancer, but the tumor is confined to the cervix. This stage is further categorized as IA and IB, which each have further subcategorizations based on the size of the tumor:
- In stage IA, the cancer cells can be seen only under a microscope. In stage IA1, there is minimal invasion (less than 3 mm and less than 7 mm wide) In stage IA2, there is deeper invasion of 3 - 5 mm) but the microscopic tumor is still less than 7 mm wide.
- In stage IB, the cancer is either visible without a microscope, or it is still microscopic but is more than 5 mm deep or 7 mm wide. Cancer that can be seen without a microscope is divided into Stage 1B1 and Stage 1B2. In stage 1B1, the cancer is smaller than 4 cm. In stage IB2, the cancer is larger than 4 cm.
Stage II. Stage II invasive cancer has spread beyond the cervix, but it has not spread to the pelvic side wall. This stage is further categorized as IIA and IIB.
- In stage IIA, the cancer has spread to the upper two-thirds of the vagina but not to the uterus.
- In stage IIB, the cancer has spread beyond the vagina into the tissues of the uterus.
Stage III. In stage III, the cancer has spread to the lower third of the vagina.
- In stage IIIA, the cancer has not spread to the pelvic wall.
- In stage IIIB, the cancer has spread to the pelvic wall. The tumor may have become large enough to block the ureters of the kidney, which can cause the kidney to stop functioning.
Stage IV. Stage IV is advanced (metastasized) cancer. The cancer has spread to other organs or parts of the body.
- In stage IVA, the cancer has spread to organs located near the cervix, such as the bladder or rectum.
- In stage IVB, the cancer has spread beyond the pelvic area to other parts of the body, such as the liver, intestinal tract, or lungs.
Treatment Options by Stage
Treatments for cervical cancer depend on the stage of the cancer. Clinical trials investigating new treatment approaches are available for all stages of cervical cancer.
Stage 0. Stage 0 cancer is carcinoma in situ (CIN III) and is considered a pre-invasive cancer. Treatment options include:
- Loop electrosurgical excision procedure (LEEP)
- Laser surgery
- Total (simple) hysterectomy (removal of uterus and cervix), for women who no longer want children
- Internal radiation therapy, for women who cannot have surgery
Stage IA1. Treatment options for stage IA1 may include:
- Total hysterectomy
- Radical hysterectomy (removal of uterus, cervix, part of vagina, and pelvic lymph nodes)
- Internal radiation therapy
Stage IA2. Treatment options for stage IA2 may include:
- Radical hysterectomy
- External beam radiation therapy plus brachytherapy (implantation of radioactive pellets)
- Radical trachelectomy (removal of the cervix but not the uterus) may be an option for some women who want to preserve fertility
Stage IB1. Treatment options for stage IB1 may include:
- Radical hysterectomy
- High-dose internal and external radiation therapy
- Radical trachelectomy
Stage IB2. Treatment options for stage 1B2 may include:
- Combination of chemotherapy and radiation therapy
- Radical hysterectomy, followed by radiation therapy (and possibly chemotherapy) if cancer cells are found.
Stage IIA. Treatment options for stage IIA may include:
- Internal and external radiation therapy
- Radiation therapy plus chemotherapy
- Radical hysterectomy followed by radiation therapy and chemotherapy
Stage IIB. Treatment options for stage IIB may include:
- Combined internal and external radiation therapy along with chemotherapy with cisplatin
- Other drugs may be given along with cisplatin
Stage III. Treatment options for stage IIIA and stage IIIB may include:
- Combined internal and external radiation therapy plus chemotherapy Stage IVA.
Treatment options for stage IVA may include:
- Combined internal and external radiation therapy plus chemotherapy
Stage IVB. Stage IVB cancer is generally not considered curable. Treatment options may include:
- Radiation therapy to relieve symptoms and improve quality of life
- Chemotherapy with cisplatin or carboplatin in combination with another drug (paclitaxel, gemcitabine, topotecan, or vinorelbine)
Recurrent Cancer. Cervical cancer may recur locally in the lymph nodes near the cervix, it may spread to distant sites, such as the lung or bones, or it may appear both locally and in distant locations. Treatment options depend on where the cancer has recurred. They include:
- Pelvic exenteration if cancer has spread to only local areas. This involves surgical removal of the cervix, uterus, vagina, and perhaps the bladder, lower colon, or rectum.
- Chemotherapy or radiation if cancer has spread to distant area.
Treatment of Pregnant Women with Cervical Cancer
Cervical cancer is one of the most common cancers diagnosed during pregnancy. To diagnose the condition, a cervical biopsy, in which a small amount of tissue is removed for diagnosis, can be performed anytime during the pregnancy. However, a cone biopsy (conization), which removes larger amounts of tissue, is typically delayed until after the first trimester to reduce the risk of causing a miscarriage. Conization does increase the risk for preterm delivery and may increase this risk for future pregnancies. The loop electrosurgical excision procedure (LEEP/LLETZ) may be performed in centers equipped to handle it, but should be reserved only for patients in whom invasive disease is strongly suspected.
Treatment of cervical cancer depends in part on whether a patient wishes to continue the pregnancy, and her desire for future fertility. For pregnant women who want to continue the pregnancy, and preserve fertility when possible, treatment options may include:
- If the abnormality is diagnosed as dysplasia or pre-invasive cancer, treatment is usually delayed until after the mother gives birth. The baby is delivered vaginally. It is rare for cervical cancer to progress from pre-invasive to invasive within the space of 1 - 2 trimesters.
- For stage 1A1, a cesarean section is performed at term, or earlier if the fetus is viable. After delivery, LEEP/LLETZ or conization is performed.
- For stages IA2 and IB1, a cesarean section and radical hysterectomy is performed when the fetus is viable. After delivery, radiation and chemotherapy is given.
- For stages IB2 - IVA, a cesarean section is performed as soon as possible. Treatment should not be delayed beyond weeks 32 - 34. For patients who have a delayed cesarean, chemotherapy may be given. After delivery, the patient is treated with radiation and chemotherapy.
- For stage IVB, a pregnancy of less than 20 weeks is terminated, and the patient is treated with chemotherapy. For pregnancies more than 20 weeks, a cesarean may be delayed while the woman receives chemotherapy.
In the early stages of cervical cancer, surgery is usually the preferred primary treatment approach. Not all women are candidates for all surgical procedures.
Surgery procedures by stage are:
- Loop Electrosurgical Excision Procedure (LEEP) and Laser Surgery. Used for pre-invasive cancer including cervical intrapethelial neoplasia (CIN) and stage 0.
- Conization. Used for treating pre-invasive cancer (CIN and stage 0) and invasive cancer stage IA1.
- Cryosurgery. Used for stage 0.
- Total (Simple) Hysterectomy. Used for stage 0, stage IA1.
- Radical Hysterectomy. Used for stage IA2, stage IB1 and 1B2, stage IIA.
- Radical Trachelectomy. Used for select women with stage IA2, stage IB1.
Loop Electrosurgical Excision Procedure
Loop electrosurgical excision procedure (LEEP), also called large loop excision of the transformation zone (LLETZ), uses a high frequency electrical current to cut away diseased tissue.
- A local anesthetic is applied to the cervix, and a wire loop is inserted into the vagina.
- A button-sized slice of tissue is removed from the cervix for examination.
- A deeper slice is used to evaluate the endocervical canal.
The procedure is done in one office visit. Extensive and deep sections of damaged tissue can be effectively removed in this visit. Disease can be cured in one treatment. When used for dysplasia, it appears to be as effective as more invasive procedures.
Laser surgery for cervical cancer uses a laser beam, in place of a knife, to burn off abnormal cells or to remove pieces tissue for biopsy. The laser beam is directed through the vagina.
Conization is a surgical procedure that removes a cone-shaped piece of tissue from the cervix. Conization uses either a heated wire, like LEEP, or it may involve a scalpel or laser (in which case the procedure is sometimes called “cone knife cone biopsy”). The surgery is performed under general anesthesia in an operating room. With conization, the ability to become pregnant can be preserved in most cases.
A hysterectomy attempts to eliminate the cancerous tissue by removing the uterus. In women of childbearing age, the ovaries can usually be left intact. Although a woman who has a hysterectomy but retains her ovaries cannot bear children, she will not go into premature menopause.
Women with cervical cancer usually have either a total (simple) hysterectomy or a radical hysterectomy.
Total Hysterectomy. A total (also called simple) hysterectomy involves the removal of the uterus and the cervix, but leaves the parametrium (tissue surrounding the uterus) and vagina intact. Lymph nodes in the pelvis are not usually removed. The uterus may be removed through an open abdominal incision or vaginally. There are various ways to perform vaginal hysterectomy, including laparoscopically. A simple hysterectomy is usually performed to treat stage IA1 cervical cancer. [For more information on hysterectomy procedures, see In-Depth Report #73: Uterine fibroids and hysterectomy.]
Click the icon to see an illustrated series detailing a hysterectomy.
Radical Hysterectomy. A radical hysterectomy removes not only the uterus and the cervix but also the parametrium, the supporting ligaments, the upper vagina, and some or all of the pelvic lymph nodes (a procedure called lymphadenectomy). The fallopian tubes and ovaries are not usually removed, (a procedure called bilateral-salpingo-oopherectomy) unless there are other medical reasons for doing so. Radical hysterectomy is used to treat cervical cancers in stages IA2, IB1, and IB2.
Pelvic Exenteration. If the cancerous tumor recurs within the pelvis after primary treatment, the patient may need a more extreme procedure called a pelvic exenteration, which combines radical hysterectomy with removal of the bladder and rectum. (In such cases, plastic surgery may be needed afterward to recreate an artificial vagina.)
Recovery. Hospital stays for simple hysterectomy range from 1 - 2 days for vaginal hysterectomy to 3 - 5 days for abdominal hysterectomy. Total recovery time is generally 2 - 3 weeks for vaginal hysterectomy and 4 - 6 weeks for abdominal hysterectomy. Radical hysterectomy generally requires a 5 - 7 hospital stay and about a 6-week recovery period.
Side Effects. Side effects include difficulty emptying the bladder or bowels and a painful lower abdomen (if an abdominal incision was used). Normal activity, including intercourse, can be resumed in about 4 - 8 weeks. The effects of hysterectomy on sexuality vary among women. Some women note a change in their orgasmic response because they no longer experience uterine contractions.
Once the uterus is removed, menstruation will cease. If the ovaries are removed, the symptoms of menopause will begin. These symptoms are likely to be more severe in surgical menopause than in natural menopause. The patient should discuss the benefits and risks of hormone replacement therapy with her doctor.
[For more information on hysterectomy, see In-Depth Report #73: Uterine fibroids and hysterectomy.]
For some women with stage IA2 and stage 1B cancer, radical trachelectomy may be a fertility-sparing alternative to hysterectomy. Radical trachelectomy involves removing the cervix, surrounding lymph nodes, and upper part of the vagina. The uterus is then reattached to the remaining vagina.
Radical trachelectomy was first introduced in 1995 and is a relatively new, and complex, procedure. Surgeons must be highly trained to perform it, and doctors must be selective about choosing women who are appropriate potential candidates. Patients must meet strict criteria in terms of lesion size and lymph node involvement.
Radical trachelectomy does pose a high risk for miscarriage during future pregnancy, but about half of women who have had this procedure have been able to carry a baby to term. The baby is delivered by cesarean section.
Radiation therapy is a treatment option for early stage cervical cancer (stages 1A2 - 1B1). Radiation given along with cisplatin-based chemotherapy is commonly used for stages IB2 - IVA cervical cancer.
There are two types of radiation therapy:
- External beam radiation uses high-energy x-rays aimed at the pelvic area from an outside machine. It usually involves a short period of direct-radiation 5 days a week for about 6 weeks in an outpatient setting.
- Internal radiation (also called brachytherapy or intracavitary radiation) is designed to deliver high doses of radiation to the local tumor area. Radioactive material encased in capsules is inserted into the uterus and placed against the cervix as close to the cancerous cells as possible. Radiation implants may also be inserted directly into the tumor using a needle. Low-dose brachytherapy usually requires a hospital stay for a few days, as the patient must remain immobilized. High-dose brachytherapy is given on an outpatient basis during several short treatments.
Both types of radiation therapy may be used together.
In order to be effective, radiation therapy must be powerful enough to destroy the cancer cells' capacity to grow and divide. This means that normal cells are also affected, which may cause significant side effects. Fortunately, healthy cells usually recover quickly from the damage, whereas abnormal cells do not.
Side Effects. Side effects of radiation therapy include fatigue, redness or dryness in the treated area, diarrhea, frequent or uncomfortable urination, and vaginal dryness, itching, or burning. After treatment, side effects usually disappear.
Long-Term Complications. Complications include proctitis (inflammation of the rectum) and cystitis (inflammation of the bladder). Radiation therapy may also cause vaginal scarring, sexual difficulties, and premature menopause in younger women.
Click the icon to see an image of the female anatomy.
Radiation itself may increase the risk for later development of cancer in the area surrounding the treated tissue. Although newer more precise radiotherapy approaches should reduce this risk, the development of secondary cancers may be of particular concern for younger patients.
Chemotherapy uses cell-killing drugs called cytotoxic drugs to destroy widespread cancer cells that have spread from the primary tumor and can no longer be treated with surgery or radiation alone. Chemotherapy is usually used along with radiation (a combination called “chemoradiation”) for treatment of stages IB1 - IVB cervical cancer. Chemotherapy can help increase the effectiveness of radiation therapy. In the most advanced cancer stage, IVB, chemotherapy is used palliatively to help relieve symptoms.
Platinum-Based Drugs. Platinum-based drugs are the main chemotherapy treatment for cervical cancer. Cisplatin is the primary drug used. Carboplatin is an alternative platinum drug that is used for treating more advanced cervical cancer.
Other drugs. Other drugs may be given alone or in combination with a platinum-based drug. They include paclitaxel, topotecan, gemcitabine, 5-FU, vinorelbine, and others.
Administration. Chemotherapy is typically given intravenously at a medical center or doctor's office. The drugs are given in cycles with a period of rest following a period of treatment, to allow recovery from the side effects.
Side Effects. Chemotherapy affects all fast-growing cells, including healthy ones. So, side effects are inevitable. Side effects occur with all chemotherapeutic drugs. They are more severe with higher doses and increase over the course of treatment. Side effects also tend to be more severe when chemotherapy is given along with radiation.
Common side effects may include:
- Nausea and vomiting. Drugs can help relieve these side effects.
- Temporary hair loss
- Loss of appetite and weight
Complications. Serious short- and long-term complications can also occur and may vary, depending on the specific drugs used. They include:
- Severe drop in white blood cell count (neutropenia). The reduction in white blood cells suppresses the immune system and makes patients more susceptible to infections.
- Reduction of blood platelets (thrombocytopenia), which can lead to bruising
- Anemia, reduction in red blood cells, is a common side effect of chemotherapy. Chemotherapy-induced anemia is usually treated with erythropoiesis-stimulating drugs, which include epoietin alfa (Epogen, Procrit) and darberpetin alfa (Aranesp). Recent studies have shown that these drugs may contribute to rapid tumor growth in patients with cervical cancer. Doctors need to follow strict dosing guidelines when administering these drugs. Patients should discuss the risks and benefits of erythropoiesis-stimulating drugs with their oncologists. [For more information, see In-Depth Report #57: Anemia ]
- Premature menopause
- Liver and kidney damage
- Problems with concentration, motor function, and memory
ACOG Committee on Gynecological Practice. ACOG Practice Bulletin No. 109: Cervical Cytology Screening. Obstet Gynecol. 2009 Dec;114(6):1409-1420.
Albrechtsen S, Rasmussen S, Thoresen S, Irgens LM, Iversen OE. Pregnancy outcome in women before and after cervical conisation: population based cohort study. BMJ. 2008 Sep 18;337:a1343. doi: 10.1136/bmj.a1343.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol. 2008 Dec;112(6):1419-44.
Apgar BS, Kittendorf AL, Bettcher CM, Wong J, Kaufman AJ. Update on ASCCP consensus guidelines for abnormal cervical screening tests and cervical histology. Am Fam Physician. 2009 Jul 15;80(2):147-55.
Castellsagué X, Díaz M, Vaccarella S, de Sanjosé S, Muñoz N, Herrero R, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 2011 Oct;12(11):1023-31. Epub 2011 Sep 12.
Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9.
Committee on Adolescent Health Care. ACOG Committee Opinion No. 436: evaluation and management of abnormal cervical cytology and histology in adolescents. Obstet Gynecol. 2009 Jun;113(6):1422-5.
Committee on Infectious Diseases; American Academy of Pediatrics. Policy statement--recommended childhood and adolescent immunization schedules--United States, 2011. Pediatrics. 2011 Feb;127(2):387-8.
Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Cervical cancer. J Natl Compr Canc Netw. 2010 Dec;8(12):1388-416.
Hunter MI, Monk BJ and Tewari KS. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. Am J Obstet Gynecol. 2008;199(1):3-9.
Hunter MI, Tewari K and Monk BJ. Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease. Am J Obstet Gynecol. 2008;199(1):10-8.
Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med. 2009 Jul 16;361(3):271-8.
Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer. 2008 Oct 1;113(7 Suppl):1980-93.
Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16): 1579-88.
Noller KL. Intraepithelial neoplasia of the lower genital tract (cervix, vulva). In: Katz VL, Lentz GM, Lobo RA, Gershenson DM, eds. Comprehensive Gynecology. 5th ed. Philadelphia, Pa: Mosby Elsevier; 2007:chap 28.
Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007 Jul 7;335(7609):28. Epub 2007 May 21.
Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009 Mar 26;360(13):1298-309.
Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011 Oct 17. [Epub ahead of print]
Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, et al. Burden of cervical cancer in the United States, 1998-2003. Cancer. 2008 Nov 15;113(10 Suppl):2855-64.
Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011 Oct 17. [Epub ahead of print]
Wright TC Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197(4): 346-55.
Wright TC Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ and Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197(4): 340-5.
Harvey Simon, MD, Editor-in-Chief, Associate Professor of Medicine, Harvard Medical School; Physician, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-
A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.